Stents safer than we thought

After sifting the deluge of stent news from Europe over the past few days, experts say that, on balance, drug-coated stents have been avenged. Though the new stents aren't suited to everyone--one study, for instance, showed that drug-eluting stents are more problematic in small blood vessels than in large ones--general benefits outweighed the general risks.

It was just a year ago, you'll recall, that two major studies first raised questions about the safety of drug-coated stents. The follow-up studies won't quash debate completely, especially since the drug-coated versions are more than twice as costly as the bare sort. But they may plug enough holes in the dike to slow the sales decline.

- here's a Johnson & Johnson press release about the follow-up trials
- read here's more from the New York Times

Related stories:
Boston Scientific deals with debt Report
Tough times for stent market  Report
The suit against Boston Scientific Report
J&J makes big cuts at Alza and Scios Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.